6990 (6990) News
Follow 6990 (6990) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Kelun-Biotech trial shows 31% lower death risk versus chemotherapy
Final overall survival results from Phase III OptiTROP-Lung04 showed sac-TMT monotherapy cut the risk of death by 31% versus a platinum doublet in EGFR-mutant NSCLC after EGFR-TKI. No new safety signals were reported aft
EQUITY | Oct 25, 2026, 11:13 AM UTC
M
Kelun-Biotech Phase III Trial Shows PFS Improvement in NSCLC
Kelun-Biotech said the OptiTROP-Lung06 trial met its primary endpoint, with sac-TMT plus pembrolizumab significantly improving progression-free survival versus platinum doublet plus pembrolizumab in first-line patients w
EQUITY | Oct 25, 2026, 10:45 AM UTC